Recent data suggest that vascular endothelial growth factor receptor inhibitor(VEGFRi)can enhance the anti-tumor activity of the anti-programmed cell death-1(anti-PD-1)antibody in colorectal cancer(CRC)with microsatel...Recent data suggest that vascular endothelial growth factor receptor inhibitor(VEGFRi)can enhance the anti-tumor activity of the anti-programmed cell death-1(anti-PD-1)antibody in colorectal cancer(CRC)with microsatellite stability(MSS).However,the comparison between this combination and standard third-line VEGFRi treatment is not performed,and reliable biomarkers are still lacking.We retrospectively enrolled MSS CRC patients receiving anti-PD-1 antibody plus VEGFRi(combination group,n=54)or VEGFRi alone(VEGFRi group,n=32),and their efficacy and safety were evaluated.We additionally examined the immune characteristics of the MSS CRC tumor microenvironment(TME)through single-cell and spatial transcriptomic data,and an MSS CRC immune cell-related signature(MCICRS)that can be used to predict the clinical outcomes of MSS CRC patients receiving immunotherapy was developed and validated in our in-house cohort.Compared with VEGFRi alone,the combination of anti-PD-1 antibody and VEGFRi exhibited a prolonged survival benefit(median progression-free survival:4.4 vs.2.0 months,P=0.0024;median overall survival:10.2 vs.5.2 months,P=0.0038)and a similar adverse event incidence.Through single-cell and spatial transcriptomic analysis,we determined ten MSS CRC-enriched immune cell types and their spatial distribution,including naive CD4+T,regulatory CD4+T,CD4+Th17,exhausted CD8+T,cytotoxic CD8+T,proliferated CD8+T,natural killer(NK)cells,plasma,and classical and intermediate monocytes.Based on a systemic meta-analysis and ten machine learning algorithms,we obtained MCICRS,an independent risk factor for the prognosis of MSS CRC patients.Further analyses demonstrated that the low-MCICRS group presented a higher immune cell infiltration and immune-related pathway activation,and hence a significant relation with the superior efficacy of pan-cancer immunotherapy.More importantly,the predictive value of MCICRS in MSS CRC patients receiving immunotherapy was also validated with an in-house cohort.Anti-PD-1 antibody combined with VEGFRi presented an improved clinical benefit in MSS CRC with manageable toxicity.MCICRS could serve as a robust and promising tool to predict clinical outcomes for individual MSS CRC patients receiving immunotherapy.展开更多
Lung cancer remains the leading cause of cancer deaths worldwide and is the most common cancer in males.Immune-checkpoint inhibitors(ICIs)that target programmed cell death protein-1(PD-1)or programmed cell death-ligan...Lung cancer remains the leading cause of cancer deaths worldwide and is the most common cancer in males.Immune-checkpoint inhibitors(ICIs)that target programmed cell death protein-1(PD-1)or programmed cell death-ligand 1(PD-L1)have achieved impressive efficacy in the treatment of non-small-cell lung cancer(NSCLC)(Pardoll,2012;Champiat et al.,2016;Gao et al.,2022).Although ICIs are usually well tolerated,they are often accompanied by immune-related adverse events(irAEs)(Doroshow et al.,2019).Non-specific activation of the immune system produces off-target immune and inflammatory responses that can affect virtually any organ or system(O'Kane et al.,2017;Puzanov et al.,2017).展开更多
基金supported by the National Natural Science Foundation of China(No.81972012).
文摘Recent data suggest that vascular endothelial growth factor receptor inhibitor(VEGFRi)can enhance the anti-tumor activity of the anti-programmed cell death-1(anti-PD-1)antibody in colorectal cancer(CRC)with microsatellite stability(MSS).However,the comparison between this combination and standard third-line VEGFRi treatment is not performed,and reliable biomarkers are still lacking.We retrospectively enrolled MSS CRC patients receiving anti-PD-1 antibody plus VEGFRi(combination group,n=54)or VEGFRi alone(VEGFRi group,n=32),and their efficacy and safety were evaluated.We additionally examined the immune characteristics of the MSS CRC tumor microenvironment(TME)through single-cell and spatial transcriptomic data,and an MSS CRC immune cell-related signature(MCICRS)that can be used to predict the clinical outcomes of MSS CRC patients receiving immunotherapy was developed and validated in our in-house cohort.Compared with VEGFRi alone,the combination of anti-PD-1 antibody and VEGFRi exhibited a prolonged survival benefit(median progression-free survival:4.4 vs.2.0 months,P=0.0024;median overall survival:10.2 vs.5.2 months,P=0.0038)and a similar adverse event incidence.Through single-cell and spatial transcriptomic analysis,we determined ten MSS CRC-enriched immune cell types and their spatial distribution,including naive CD4+T,regulatory CD4+T,CD4+Th17,exhausted CD8+T,cytotoxic CD8+T,proliferated CD8+T,natural killer(NK)cells,plasma,and classical and intermediate monocytes.Based on a systemic meta-analysis and ten machine learning algorithms,we obtained MCICRS,an independent risk factor for the prognosis of MSS CRC patients.Further analyses demonstrated that the low-MCICRS group presented a higher immune cell infiltration and immune-related pathway activation,and hence a significant relation with the superior efficacy of pan-cancer immunotherapy.More importantly,the predictive value of MCICRS in MSS CRC patients receiving immunotherapy was also validated with an in-house cohort.Anti-PD-1 antibody combined with VEGFRi presented an improved clinical benefit in MSS CRC with manageable toxicity.MCICRS could serve as a robust and promising tool to predict clinical outcomes for individual MSS CRC patients receiving immunotherapy.
文摘Lung cancer remains the leading cause of cancer deaths worldwide and is the most common cancer in males.Immune-checkpoint inhibitors(ICIs)that target programmed cell death protein-1(PD-1)or programmed cell death-ligand 1(PD-L1)have achieved impressive efficacy in the treatment of non-small-cell lung cancer(NSCLC)(Pardoll,2012;Champiat et al.,2016;Gao et al.,2022).Although ICIs are usually well tolerated,they are often accompanied by immune-related adverse events(irAEs)(Doroshow et al.,2019).Non-specific activation of the immune system produces off-target immune and inflammatory responses that can affect virtually any organ or system(O'Kane et al.,2017;Puzanov et al.,2017).
